SPDR S&P Biotech ETF Rating $89.89 -1.46 (-1.60%) (As of 05:45 PM ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings SPDR S&P Biotech ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.77Holdings in XBI have an aggregate rating of Moderate Buy based on 747 analyst ratings issued in the past year covering 50 companies (74.9% of the portfolio).XBI Aggregate Price Target$89.89High Prediction$89.89Average Prediction$89.89Low Prediction$89.89Holdings in XBI have an aggregate price target of $89.89 and a range of $89.89 to $89.89 covering 50 companies (74.9% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy16 Buy rating(s)Moderate Buy28 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 XBI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.51%NBIXNeurocrine Biosciences$137.06-1.7%4.9462 of 5 stars2.83$166.29 21.3%232.40%ABBVAbbVie$176.20-1.0%4.9356 of 5 stars2.88$205.70 16.7%242.37%GILDGilead Sciences$92.01-2.2%4.6532 of 5 stars2.67$96.43 4.8%27Short Interest ↓2.36%BMRNBioMarin Pharmaceutical$65.45-2.2%4.9986 of 5 stars2.74$94.20 43.9%23Short Interest ↓Positive News2.36%UTHRUnited Therapeutics$357.64-0.6%4.4465 of 5 stars2.73$370.86 3.7%15Positive News2.28%NTRANatera$158.55-1.1%2.2288 of 5 stars3.00$152.67 -3.7%15Positive News2.27%AMGNAmgen$259.30-1.3%4.7727 of 5 stars2.40$319.67 23.3%252.26%INCYIncyte$68.42-1.2%4.6262 of 5 stars2.35$76.29 11.5%202.26%SRPTSarepta Therapeutics$121.19-0.3%4.9101 of 5 stars2.91$178.71 47.5%22Positive News2.24%PCVXVaxcyte$81.99+1.3%1.7422 of 5 stars3.00$145.71 77.7%82.24%ALNYAlnylam Pharmaceuticals$236.01-0.8%4.675 of 5 stars2.71$298.09 26.3%24Analyst Upgrade2.23%BIIBBiogen$150.19-0.7%4.8648 of 5 stars2.45$242.68 61.6%29Analyst DowngradeShort Interest ↓2.23%INSMInsmed$68.87-1.1%3.1566 of 5 stars3.00$83.67 21.5%16Positive News2.19%EXASExact Sciences$56.20-2.3%4.8132 of 5 stars2.94$72.94 29.8%18Short Interest ↓Positive News2.17%MRNAModerna$39.38-1.9%4.5033 of 5 stars2.14$79.50 101.9%22Options Volume2.17%REGNRegeneron Pharmaceuticals$702.59-1.4%4.4357 of 5 stars2.70$1,052.90 49.9%232.03%VRTXVertex Pharmaceuticals$399.35-2.3%4.2702 of 5 stars2.52$494.04 23.7%31Analyst Revision2.01%VKTXViking Therapeutics$39.77-3.4%3.8215 of 5 stars3.15$106.75 168.4%13Gap Down1.87%TGTXTG Therapeutics$31.44-3.4%4.5158 of 5 stars2.83$40.67 29.3%61.80%MDGLMadrigal Pharmaceuticals$311.62-0.5%4.1414 of 5 stars2.69$347.33 11.5%13Positive News1.79%HALOHalozyme Therapeutics$47.99-0.3%4.9639 of 5 stars2.60$61.11 27.3%10Analyst ForecastNews Coverage1.59%ADMAADMA Biologics$17.49+0.2%4.0137 of 5 stars3.25$21.25 21.5%4Positive News1.50%IONSIonis Pharmaceuticals$34.92-2.8%4.1213 of 5 stars2.68$60.65 73.7%191.49%ROIVRoivant Sciences$11.43-3.1%3.4131 of 5 stars2.88$17.93 56.9%81.41%CYTKCytokinetics$47.15-0.4%4.0848 of 5 stars2.75$84.07 78.3%161.40%APLSApellis Pharmaceuticals$31.90-2.4%4.7218 of 5 stars2.70$49.94 56.6%20Short Interest ↓1.40%BPMCBlueprint Medicines$86.82-2.9%2.8327 of 5 stars2.65$123.33 42.1%20Positive News1.33%RVMDRevolution Medicines$43.17-2.4%4.2044 of 5 stars3.09$65.82 52.5%111.24%EXELExelixis$33.70-0.3%4.6999 of 5 stars2.53$32.44 -3.7%19Short Interest ↓1.22%BBIOBridgeBio Pharma$27.32-2.4%4.5371 of 5 stars2.86$48.08 76.0%141.17%CRSPCRISPR Therapeutics$38.65-3.4%2.5864 of 5 stars2.44$77.93 101.6%181.08%ALKSAlkermes$28.78-2.6%4.7409 of 5 stars2.58$35.42 23.1%12Short Interest ↓Positive News1.02%SMMTSummit Therapeutics$17.89-1.8%1.8736 of 5 stars2.83$33.33 86.3%60.98%RNAAvidity Biosciences$29.18-3.1%2.3174 of 5 stars3.00$64.36 120.6%110.95%ACLXArcellx$78.35-0.9%3.0636 of 5 stars3.13$105.93 35.2%150.87%NUVLNuvalent$77.87-3.0%2.9836 of 5 stars2.86$112.36 44.3%14Analyst Forecast0.85%BHVNBiohaven$35.78-2.4%3.79 of 5 stars3.07$63.00 76.1%140.80%SWTXSpringWorks Therapeutics$36.340.0%1.85 of 5 stars3.00$69.50 91.2%6Positive News0.79%TWSTTwist Bioscience$47.23-2.0%3.339 of 5 stars2.70$51.90 9.9%10Gap Down0.78%RAREUltragenyx Pharmaceutical$42.27-2.6%4.4897 of 5 stars2.92$88.46 109.3%130.77%KRYSKrystal Biotech$159.80+0.3%4.588 of 5 stars3.00$206.67 29.3%80.77%CRNXCrinetics Pharmaceuticals$50.67-2.3%3.8212 of 5 stars3.00$74.40 46.8%10Positive News0.73%RXRXRecursion Pharmaceuticals$6.77-8.4%2.8943 of 5 stars2.40$9.25 36.6%5Gap Down0.72%IOVAIovance Biotherapeutics$7.17-2.7%4.2837 of 5 stars2.88$23.00 220.8%8Positive News0.70%DYNDyne Therapeutics$23.65-0.3%3.0978 of 5 stars3.08$50.42 113.2%13Positive News0.70%GERNGeron$3.40+1.5%3.5627 of 5 stars3.09$7.15 110.3%11High Trading Volume0.68%PTGXProtagonist Therapeutics$38.51-1.2%2.8763 of 5 stars3.00$53.78 39.6%9Positive News0.66%CLDXCelldex Therapeutics$25.12-1.1%2.4285 of 5 stars2.88$62.25 147.8%8Short Interest ↓0.65%VCYTVeracyte$40.00-0.3%4.4429 of 5 stars2.67$41.13 2.8%9Short Interest ↓Positive News0.65%VERAVera Therapeutics$42.06+1.6%3.3907 of 5 stars3.11$63.50 51.0%9Positive News This page (NYSEARCA:XBI) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
